Pooling 47 randomized controlled trials, SGLT2 inhibitor therapy produced no statistically significant reductions in C-reactive protein/hsCRP (MD −1.13 mg/L; 95% CI −2.31 to 0.05) or IL-6 (MD −1.53 pg/mL; 95% CI −3.69 to 0.64). TNF-α showed a modest standardized mean difference of −0.39, but its prediction interval crossed the null, meaning the effect may not replicate in future trials. Heterogeneity was extreme across all biomarkers (I² > 70%), and the authors rated evidence certainty as very low.
SGLT2 inhibitors — empagliflozin, dapagliflozin, canagliflozin — have earned landmark status in cardiology and nephrology based on cardiovascular outcome trials showing reduced hospitalizations for heart failure, slowed kidney disease progression, and cardiovascular mortality reduction. Inflammation has been proposed as one mechanistic pillar explaining these benefits, alongside glycosuria-driven caloric loss, blood pressure reduction, and cardiorenal hemodynamic effects. This rigorous meta-analysis substantially weakens the inflammation hypothesis, at least as measured by peripheral blood biomarkers.
The finding is clinically important rather than paradigm-shifting: it redirects mechanistic focus toward non-inflammatory pathways and cautions against marketing SGLT2is as anti-inflammatory agents. Key limitations include extreme heterogeneity likely driven by differences in background disease, duration, and dosing, plus reliance on circulating rather than tissue-level markers. For patients and clinicians, the proven cardiovascular and renal benefits remain intact — the mechanism just may not run primarily through systemic inflammation.